The Role of Tumor Mutational Burden in Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Dixie-Lee Esseltine, MD and George Mulligan, PhD offer insight on the impact of ixazomib on Takeda Oncology’s approach to multiple myeloma care and its approach to other cancer types.
Linda Bosserman discusses the issues regarding the value of personalized care